Early Effects of Intensive Lipid Lowering Treatment With Ezetimibe/ Simvastatin (Vytorin®) Assessed by Virtual Histology-Intravascular Ultrasound (VH-IVUS) and Optical Coherence Tomography (OCT) on Plaque Characteristics in Patients With Acute Coro

• Status: Completed
• Trial end date: 2014-01-01

Summary

Objective: To evaluate the early effects of intensive lipid lowering treatments with ezetimibe/simvastatin (Vytorin®) for each component of coronary plaques.

Study Design

• Prospective, randomized, single-center study of each 80 subjects enrolled

• Subjects with acute coronary syndrome who meet all inclusion and exclusion criteria will be enrolled.

• Eligible subjects will be randomized 1:1 to A) Ezetimibe/Simvastatin (n=80) vs. B) Pravastatin (n=80), and each group of patients will be randomized further in a ratio of 1:1 to a) ZES (n=40) vs. b) EES (n=40), according to the type of stent used.

• All subjects will undergo VH-IVUS at initial procedure.

• Follow-up VH-IVUS will be performed at 3 months after index procedure. OCT at initial procedure and 3-months will be performed in available cases.

• Phase: Phase 4

Details

• Lead Sponsor: Yonsei University
• Treatments: Everolimus; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Pravastatin; Simvastatin